A detailed history of Geode Capital Management, LLC transactions in Verona Pharma PLC stock. As of the latest transaction made, Geode Capital Management, LLC holds 62,081 shares of VRNA stock, worth $2.81 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
62,081
Previous 65,944 5.86%
Holding current value
$2.81 Million
Previous $953,000 87.41%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$15.46 - $30.16 $59,721 - $116,508
-3,863 Reduced 5.86%
62,081 $1.79 Million
Q2 2024

Aug 09, 2024

BUY
$11.48 - $17.02 $6,566 - $9,735
572 Added 0.87%
65,944 $953,000
Q1 2024

May 13, 2024

BUY
$15.3 - $20.24 $65,162 - $86,202
4,259 Added 6.97%
65,372 $1.05 Million
Q4 2023

Feb 13, 2024

BUY
$11.94 - $20.47 $102,970 - $176,533
8,624 Added 16.43%
61,113 $1.21 Million
Q3 2023

Nov 13, 2023

BUY
$16.3 - $22.09 $122,201 - $165,608
7,497 Added 16.66%
52,489 $855,000
Q2 2023

Aug 11, 2023

BUY
$19.41 - $23.43 $236,840 - $285,892
12,202 Added 37.21%
44,992 $951,000
Q1 2023

May 15, 2023

BUY
$18.06 - $25.27 $20,516 - $28,706
1,136 Added 3.59%
32,790 $658,000
Q4 2022

Feb 13, 2023

SELL
$9.84 - $26.13 $105,248 - $279,486
-10,696 Reduced 25.26%
31,654 $827,000
Q3 2022

Nov 14, 2022

BUY
$4.14 - $13.59 $115,559 - $379,337
27,913 Added 193.34%
42,350 $432,000
Q1 2022

May 13, 2022

BUY
$4.82 - $6.98 $5,610 - $8,124
1,164 Added 8.77%
14,437 $72,000
Q4 2021

Feb 11, 2022

BUY
$3.91 - $7.08 $10,033 - $18,167
2,566 Added 23.97%
13,273 $89,000
Q3 2021

Nov 12, 2021

BUY
$5.29 - $6.35 $56,640 - $67,989
10,707 New
10,707 $58,000

Others Institutions Holding VRNA

About Verona Pharma plc


  • Ticker VRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,954,200
  • Market Cap $2.76B
  • Description
  • Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...
More about VRNA
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.